See more : PT Bima Sakti Pertiwi Tbk (PAMG.JK) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCielo Ltd. (PCLOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCielo Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Xiamen ITG Group Corp.,Ltd (600755.SS) Income Statement Analysis – Financial Results
- RediShred Capital Corp. (RDCPF) Income Statement Analysis – Financial Results
- Groupe Plus-Values SA (MLPVG.PA) Income Statement Analysis – Financial Results
- Lipigon Pharmaceuticals AB (publ) (LPGO.ST) Income Statement Analysis – Financial Results
- Samsung Fire & Marine Insurance Co., Ltd. (000815.KS) Income Statement Analysis – Financial Results
PharmaCielo Ltd. (PCLOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharmacielo.com
About PharmaCielo Ltd.
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54M | 5.31M | 1.94M | 2.65M | 786.90K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.91M | 4.48M | 6.25M | 9.45M | 2.45M | 653.63K | 26.87K | 68.40K | 32.74K |
| Gross Profit | -1.37M | 827.06K | -4.31M | -6.80M | -1.66M | -653.63K | -26.87K | -68.40K | -32.74K |
| Gross Profit Ratio | -88.78% | 15.58% | -221.51% | -256.19% | -210.90% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.81M | 10.70M | 17.94M | 31.21M | 29.63M | 118.61K | 12.80M | 5.40M | 3.35M |
| Selling & Marketing | 411.96K | 779.19K | 1.08M | 1.13M | 900.66K | 1.31M | -12.79M | 1.16M | 737.91K |
| SG&A | 8.22M | 11.48M | 19.01M | 32.34M | 30.53M | 118.61K | 15.98K | 6.56M | 4.09M |
| Other Expenses | -9.59M | 873.13K | 136.63K | 949.03K | -218.73K | -25.79K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -1.37M | 12.26M | 20.89M | 36.62M | 32.67M | 118.61K | 15.98K | 11.19M | 4.16M |
| Cost & Expenses | 11.24M | 16.74M | 27.14M | 46.07M | 35.12M | 118.61K | 15.98K | 11.26M | 4.20M |
| Interest Income | 176.00 | 1.83K | 2.37K | 65.58K | 585.13K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.86M | 1.54M | 561.29K | 272.73K | 173.84K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.41M | 1.58M | 1.32M | 1.48M | 1.28M | 653.63K | 806.55K | 32.83K | 5.61K |
| EBITDA | -12.19M | -9.88M | -24.84M | -41.92M | -32.68M | -30.98M | -15.98K | -6.65M | -4.12M |
| EBITDA Ratio | -790.59% | -186.12% | -1,244.64% | -1,565.79% | -4,153.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.70M | -11.46M | -25.46M | -43.12M | -33.96M | -118.61K | -15.98K | -6.69M | -4.12M |
| Operating Income Ratio | -629.22% | -215.87% | -1,309.24% | -1,624.81% | -4,316.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.60M | -3.08M | -1.44M | -634.62K | -703.86K | 31.44M | -16.36M | -4.58M | -71.45K |
| Income Before Tax | -16.30M | -14.52M | -26.63M | -43.76M | -34.67M | -144.40K | -15.98K | -11.26M | -4.20M |
| Income Before Tax Ratio | -1,057.09% | -273.45% | -1,369.14% | -1,648.73% | -4,405.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.57M | 288.00K | 504.42K | -44.88K | -161.14K | -806.55K | 216.34 | 0.00 |
| Net Income | -16.30M | -14.52M | -26.63M | -43.76M | -34.67M | -144.40K | -15.98K | -11.26M | -4.20M |
| Net Income Ratio | -1,057.09% | -273.45% | -1,369.14% | -1,648.73% | -4,405.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.10 | -0.18 | -0.39 | -0.36 | -1.18 | -0.04 | -0.22 | -0.18 |
| EPS Diluted | -0.10 | -0.10 | -0.18 | -0.39 | -0.36 | -1.18 | -0.04 | -0.22 | -0.18 |
| Weighted Avg Shares Out | 160.08M | 150.98M | 145.64M | 112.54M | 96.05M | 122.19K | 388.61K | 50.68M | 22.98M |
| Weighted Avg Shares Out (Dil) | 160.08M | 150.98M | 145.64M | 112.54M | 96.05M | 122.19K | 388.61K | 50.68M | 22.98M |
Colombian Government Continues its Support of Domestic Cannabis Industry - Resolution Extending THC Inventory Allowance Provides Immediate Benefit to PharmaCielo
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 1, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings...
Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products
Austin, Texas and Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - January 4, 2024) - Benuvia Operations, LLC ("Benuvia"), a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, and PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo"), the Canadian...
PharmaCielo Announces Q3 2023 Financial Results
All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - November 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of...
PharmaCielo Raises $3.3 Million Under Previously Announced Non-Brokered Private Placement
Today the Company closed the latest tranche consisting of 1,500 units for aggregate proceeds of $1,500,000. The Company also announced that it has agreed to issue shares and debt in settlement of certain amounts owing.
PharmaCielo Announces Q2 2023 Financial Results
All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of...
PharmaCielo Provides Corporate Update
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 10, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings...
PharmaCielo Announces Appointment of Marc Lustig as Chairman and CEO
Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - July 11, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings...
PharmaCielo Stock Dives On Heels Of Closing Initial Tranche Of $3.92M Offering
PharmaCielo Ltd. (TSXV:PCLO) (OTCQX:PCLOF), the Canadian parent of Colombia's cannabis company PharmaCielo Colombia Holdings S.A.S.
Source: https://incomestatements.info
Category: Stock Reports